Wordt geladen...
Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
BACKGROUND: Monoclonal antibodies (mAbs) targeting the CGRP pathway are safe and efficacious therapies for the prevention of migraine. In this study we assessed the effects of discontinuation of preventive erenumab and galcanezumab treatment in patients with chronic migraine. METHODS: This retrospec...
Bewaard in:
| Gepubliceerd in: | J Headache Pain |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Springer Milan
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6734267/ https://ncbi.nlm.nih.gov/pubmed/31159727 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s10194-019-1018-8 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|